Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 16;16(1):22.
doi: 10.1186/s12902-016-0104-z.

Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden

Clare Jamookeeah  1 , Paul Robinson  1 , Karl O'Reilly  2 , Johan Lundberg  3 , Martin Gisby  1 , Michael Ländin  3 , Jakob Skov  4 , David Trueman  5
Affiliations

Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden

Clare Jamookeeah et al. BMC Endocr Disord. .

Abstract

Background: Tolvaptan is the only vasopressin V2 receptor antagonist licensed by the European Medicines Agency for the treatment of hyponatraemia (HN) secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). We have investigated the cost-effectiveness of tolvaptan versus no active treatment (NAT) in adult patients within the licensed indication who have either failed to respond to fluid restriction or for whom the use of fluid restriction is not suitable, from the societal perspective in Sweden.

Methods: A cost-utility analysis, considering a 'general SIADH' population and two subpopulations of patients (small-cell lung cancer [SCLC] and pneumonia) to broadly represent the complex clinical pathway of SIADH, was performed. A discrete event simulation was developed to model the progression of individuals through inpatient admissions over a 30-day time horizon (180 days for the SCLC cohort). Clinical data were derived from tolvaptan trials and observational data sources. All costs are given in Swedish kronor (SEK).

Results: In the 'general SIADH' population, tolvaptan was associated with reduced costs (SEK 5,779 per patient [€624]) and increased quality-adjusted life-years (QALYs) (0.0019) compared with NAT and was therefore the dominant treatment strategy. Tolvaptan was also associated with reduced costs and increased QALYs in the SCLC and pneumonia subpopulations. The most influential variables in our analysis were reduction in hospital length of stay, duration of treatment and long term treatment with tolvaptan in SCLC patients.

Conclusions: Tolvaptan represents a cost-effective treatment option in Sweden for hospitalised patients with HN secondary to SIADH who have either failed to respond to or are unsuitable for fluid restriction.

Keywords: Cost-effectiveness; Cost-utility; Discrete event simulation; Hyponatraemia; SIADH; Tolvaptan.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Event graph depicting flow of patients in model
Fig. 2
Fig. 2
Tornado diagram showing effect of varying parameters on NMB (threshold = SEK 1.2 m). Abbreviations: HRQL, health-related quality of life; LOS, length of stay; NAT, no active treatment; NMB, net monetary benefit; OR, odds ratio; SEK, Swedish kronor
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Swedish Endocrine Society. Svenskt vardprogram for hyponatremi. 2012. Available from: http://endokrinologforeningen.se/documents/Svenskt%20vardprogram%20for%2... [Accessed 10 Aug 2015]
    1. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1–47. doi: 10.1530/EJE-13-1020. - DOI - PubMed
    1. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med. 1985;102(2):164–8. doi: 10.7326/0003-4819-102-2-164. - DOI - PubMed
    1. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol Suppl. 2011;164(5):725–32. doi: 10.1530/EJE-10-1078. - DOI - PMC - PubMed
    1. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Salt Investigators: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–112. doi: 10.1056/NEJMoa065181. - DOI - PubMed

LinkOut - more resources